The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Ozempic is sold in injection pens containing 0.25 and 0.5mg doses ... It was later marketed in a long-acting form under the brand name Bydureon BCise. Byetta was registered for use in South Africa in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) that require injection once a week or less are now available to prescribers in the form of Bydureon®(once-weekly exenatide).

Common side effects include nausea, diarrhea, headache, and injection site reactions. For full details on side effects, see the Bydureon BCise medication guide or talk to your healthcare provider.

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

They were either given weekly exenatide injections or a placebo jab. At the end of the 96-week study those taking exenatide, sold under the brand Bydureon in the UK, saw no benefits compared to ...

One major angle has been the race to develop an oral weight loss treatment, which would provide a significant boost to convenience over current treatments that require an injection. As well as ...